ATE402995T1 - Akt-3 nukleinsäure, polypeptide und deren verwendung - Google Patents

Akt-3 nukleinsäure, polypeptide und deren verwendung

Info

Publication number
ATE402995T1
ATE402995T1 AT00917899T AT00917899T ATE402995T1 AT E402995 T1 ATE402995 T1 AT E402995T1 AT 00917899 T AT00917899 T AT 00917899T AT 00917899 T AT00917899 T AT 00917899T AT E402995 T1 ATE402995 T1 AT E402995T1
Authority
AT
Austria
Prior art keywords
polypeptides
act
nucleic acid
akt3
relates
Prior art date
Application number
AT00917899T
Other languages
English (en)
Inventor
Kun Guo
Marco Pagnoni
Kenneth Clark
Yuri Ivashchenko
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE402995T1 publication Critical patent/ATE402995T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00917899T 1999-03-19 2000-03-14 Akt-3 nukleinsäure, polypeptide und deren verwendung ATE402995T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
ATE402995T1 true ATE402995T1 (de) 2008-08-15

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917899T ATE402995T1 (de) 1999-03-19 2000-03-14 Akt-3 nukleinsäure, polypeptide und deren verwendung

Country Status (18)

Country Link
EP (1) EP1144600B1 (de)
JP (1) JP4237945B2 (de)
KR (1) KR100700908B1 (de)
AT (1) ATE402995T1 (de)
AU (1) AU782448B2 (de)
BR (1) BR0009170A (de)
CA (1) CA2343074C (de)
CY (1) CY1108459T1 (de)
DE (1) DE60039677D1 (de)
DK (1) DK1144600T3 (de)
ES (1) ES2310515T3 (de)
HK (1) HK1041288B (de)
IL (4) IL145514A0 (de)
NO (1) NO20014537L (de)
PT (1) PT1144600E (de)
SI (1) SI1144600T1 (de)
WO (1) WO2000056866A2 (de)
ZA (1) ZA200108414B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
CA2369764A1 (en) 1999-04-16 2000-10-26 Yale University Enos mutations useful for gene therapy and therapeutic screening
CA2376630A1 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
JPWO2003063905A1 (ja) * 2002-01-31 2005-05-26 株式会社東京大学Ｔｌｏ 免疫疾患の予防又は治療剤
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
WO2005009470A1 (ja) * 2003-07-28 2005-02-03 Osaka Industrial Promotion Organization Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法
EP2599793A1 (de) 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-Phosphor-AKT-Antikörper
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
SI2588475T1 (sl) 2010-07-02 2015-12-31 Gilead Sciences, Inc. Kinazni inhibitorji za regulacijo apoptoznega signala
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP2017528471A (ja) 2014-09-24 2017-09-28 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
ES2842749T3 (es) 2014-12-23 2021-07-14 Gilead Sciences Inc Procesos para preparar inhibidores de ASK1
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
US20220143217A1 (en) * 2019-03-04 2022-05-12 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
PT862622E (pt) * 1995-11-16 2005-01-31 Novartis Ag Metodo de rastreio para compostos que interagem com proteina cinase rac
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
CA2376630A1 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Also Published As

Publication number Publication date
JP2002539781A (ja) 2002-11-26
BR0009170A (pt) 2002-04-30
EP1144600B1 (de) 2008-07-30
IL145514A (en) 2010-05-17
HK1041288B (en) 2008-11-07
IL141984A0 (en) 2002-03-10
ZA200108414B (en) 2003-03-26
CA2343074A1 (en) 2000-09-28
IL190270A (en) 2012-12-31
DE60039677D1 (de) 2008-09-11
EP1144600A2 (de) 2001-10-17
DK1144600T3 (da) 2008-11-24
WO2000056866A3 (en) 2001-02-15
KR20020011972A (ko) 2002-02-09
CA2343074C (en) 2010-09-21
JP4237945B2 (ja) 2009-03-11
WO2000056866A2 (en) 2000-09-28
NO20014537L (no) 2001-10-31
ES2310515T3 (es) 2009-01-16
WO2000056866A9 (en) 2002-08-29
PT1144600E (pt) 2008-10-10
CY1108459T1 (el) 2013-09-04
IL145514A0 (en) 2002-06-30
AU3880200A (en) 2000-10-09
HK1041288A1 (en) 2002-07-05
AU782448B2 (en) 2005-07-28
NO20014537D0 (no) 2001-09-18
SI1144600T1 (sl) 2008-12-31
KR100700908B1 (ko) 2007-03-29

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
DE3684892D1 (de) Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens.
DE602005021509D1 (de) Modifizierte vitamin-k-abhängige polypeptide
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
ATE419357T1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
TR200102985T2 (tr) Gen tedavisi teknikleri.
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
NZ516237A (en) Meth1 and meth2 polynucleotides and polypeptides
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
DK0676413T3 (da) Inteferon-alfa/beta-bindingsprotein, dets fremstilling og anvendelse
BRPI0415296A (pt) cdna modificado para os nìveis de expressão elevados do fator viii e seus derivados
Basílico et al. UV-specific DNA repair recombinant fusion enzyme: A new stable pharmacologically active principle suitable for photoprotection
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
EP1427825B8 (de) Menschliche alpha2-delta4-calciumkanal-untereinheit codierende cdna
WO2002034882A3 (en) Genes regulating programmed cell death
CY1113344T1 (el) Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1144600

Country of ref document: EP